Degludec outperforms glargine in curbing nocturnal hypoglycemia

05/6/2013 | Healio

Type 1 diabetes patients who received high-dose insulin degludec once daily showed lower rates of nocturnal hypoglycemia than their counterparts who took insulin glargine, a study showed. The findings were presented at the American Association of Clinical Endocrinologists annual meeting.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI